Novavax Tests New Vaccine To Fight Varients
NOVAVAX BEGINS TESTING ON A COVID VACCINE TO TARGET SOUTH AFRICAN VARIANT
(CNN) – Biotechnology company Novavax says it is testing a new version of its COVID-19 vaccine.
Scientists are specifically targeting the coronavirus variant first identified in South Africa.
Once lab testing is complete, the new vaccine could move to clinical trials.
But research is still in the early phases.
Meanwhile, Novavax says the U.S. trial for its original vaccine has reached full enrollment.
In January, the company announced early results from a phase three trial in the U.K. showed an efficacy of 89%.
Novavax says if everything stays on track in the U.S. the vaccine could have emergency use authorization by summer.